Proscia Named To Inc.’s 2024 Best In Business List
Proscia: Recognized for product and customer traction in accelerating digital pathology market
Philadelphia – December 3, 2024 – Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, has been named to Inc.’s 2024 Best in Business. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and society at large.
Proscia’s recognition comes as digital pathology experiences a surge in demand. Digital pathology continues to overcome systemic challenges plaguing the microscope-based practice; the pathologist population declined by 17.5% in a decade¹ while the global cancer burden is expected to increase by 77% to 35.3 million cases by 20502 . Digital pathology is also enabling a new wave of precision medicine driven by accelerating advancements in AI. Each pathology image contains billions of pixels providing one of the most detailed and direct profiles of diseases like cancer, giving rise to insights that can guide the next novel therapies and diagnostics and inform up to 70% of clinical decisions3.
“This award from Inc. culminates a tremendous year for Proscia,” said David West, CEO. “The impact of digital pathology has grown exponentially, reshaping the care patients can receive. We thank our customers, partners, and team for helping us to capitalize on this potential as we advance our mission to change the way we fight diseases like cancer.”
Proscia was honored in the Health Products category for the momentum around its Concentriq enterprise pathology platform. Most recently, Concentriq was named to KLAS Research’s Emerging Solutions Top 20 for improving patient outcomes. This follows a report from KLAS indicating that 100% of Proscia’s customers surveyed would buy Concentriq again. Concentriq is used by 14 of the top 20 pharmaceutical companies and major diagnostic laboratories around the world.
Among its other product and customer milestones, Proscia announced that it had grown its clinical customer base by more than 100% year-over-year. It also secured FDA clearance for its Concentriq® AP-Dx in February 2024. The company additionally released findings from a study conducted with Quest Diagnostics, a leading provider of diagnostic information services, on the impact of AI-enabled workflows; pathologists were able to sign out 2.9 cases per hour instead of 1.2.
“For over 40 years, Inc. has been committed to recognizing America’s most dynamic businesses and honoring the great work they do. These businesses have had a profound impact on their industries, solving important problems, and shaping the future of business in ways that will have lasting effects,” said Inc. editor-in-chief Mike Hofman.
The fifth annual Best in Business list recognized 241 companies across a wide range of industries. Proscia was selected from thousands of nominees and listed alongside companies including Okta, Oura, and Salesforce.
The full list can be found here and in the upcoming winter print edition of Inc. magazine.
About Inc.
Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of our community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating our future. Inc.’s award-winning work achieves a monthly brand footprint of more than 40 million across a variety of channels, including events, digital, print, video, podcasts, newsletters, and social media. Its proprietary Inc. 5000 list, produced every year since its launch as the Inc. 100 in 1982, analyzes company data to rank the fastest-growing privately held businesses in the United States. The recognition that comes with inclusion on this and other prestigious Inc. lists, such as Female Founders and Power Partners, gives the founders of top businesses the opportunity to engage with an exclusive community of their peers, and credibility that helps them drive sales and recruit talent. For more information, visit www.inc.com.
About Proscia
Proscia is a software company accelerating pathology’s transition to a digital, data-driven discipline and enabling AI to advance precision medicine. Its Concentriq enterprise pathology platform, precision medicine AI portfolio, and real-world data fuel the development and use of novel therapies and diagnostics to drive the fight against humanity’s most challenging diseases, like cancer. 14 of the top 20 pharmaceutical companies and a global network of diagnostic laboratories rely on Proscia’s solutions each day. The company has FDA 510(k) clearance and CE-IVDR certification for its diagnostic software. For more information, visit proscia.com, and follow Proscia on LinkedIn and X.
1. DM, Colgan TJ, Leung ST, Timmons CF, Park JY. Trends in the US and Canadian Pathologist Workforces From 2007 to 2017. JAMA Netw Open. 2019 May 3;2(5):e194337. doi: 10.1001/jamanetworkopen.2019.4337. PMID: 31150073; PMCID: PMC6547243.
2. Bizuayehu HM, Ahmed KY, Kibret GD, et al. Global Disparities of Cancer and Its Projected Burden in 2050. JAMA Netw Open. 2024;7(11):e2443198. doi:10.1001/jamanetworkopen.2024.43198
3. NHS England (2017). Digital First: Clinical Transformation Through Pathology Innovation. National Pathology Programme; doi: https://www.england.nhs.uk/wp-content/uploads/2014/02/pathol-dig-first.pdf
SOURCE: Proscia
